Company intelligence / Profile preview

Spyre Therapeutics, Inc.

Waltham, Massachusetts, United States of America

Ownership: Public · SYRE
Employees: ~65
Development stage: Phase 1

Overview

SPY001 (α4β7) showed favorable safety profile in Phase 1 with half-life estimates >90 days supporting potential Q6M maintenance dosing. Phase 2 trial in UC planned for mid-2025. Interim Phase 1 data readouts for SPY002 and SPY003 expected in Q2 and H2 2025, respectively.

Therapeutic areas: GastroenterologyRheumatology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

18 assets

arginase-1

17 more assets in the full pipeline.

Request access →

Partnerships

Paragon Therapeutics

Financials

Market cap: $7.7B
Total revenue: $0
Enterprise value: $6.6B

Beyond the preview

Go deeper on Spyre Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spyre Therapeutics, Inc..

Explore the full profile